In non-small cell lung cancer, BPTF positive regulation of VEGF, BPTF high expression can predict better efficacy of bevacizumab, while BPTF low expression can predict poor efficacy of bevacizumab. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.